HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Luca Lanfranco Selected Research

Kidney Transplantation

1/2017Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Luca Lanfranco Research Topics

Disease

1Lupus Nephritis
12/2021
1Polyneuropathies (Polyneuropathy)
12/2021
1Membranous Glomerulonephritis (Membranous Nephropathy)
12/2021
1Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
01/2020
1Polyradiculoneuropathy (Polyradiculoneuritis)
01/2020
1Neoplasms (Cancer)
10/2018
1Thrombotic Microangiopathies
01/2017
1Ocular Toxoplasmosis
12/2016

Drug/Important Bio-Agent (IBA)

2AntibodiesIBA
12/2021 - 01/2020
2Contactin 1IBA
12/2021 - 01/2020
1AntigensIBA
12/2021
1AutoantibodiesIBA
12/2021
1Proteins (Proteins, Gene)FDA Link
12/2021
1Immunoglobulin G (IgG)IBA
01/2020
1Glycoproteins (Glycoprotein)IBA
01/2020
1Immune Checkpoint InhibitorsIBA
10/2018
1Monoclonal AntibodiesIBA
10/2018
1Biological ProductsIBA
01/2017
1eculizumabFDA Link
01/2017
1Abatacept (Orencia)FDA Link
12/2016

Therapy/Procedure

1Kidney Transplantation
01/2017